Rebekka C. Noll is an associate in the Litigation Department. Her practice focuses on patent litigation and prosecution and her work encompasses all aspects of biotechnology, with a focus on vector-based delivery technologies for gene and immunotherapeutic approaches to infectious diseases and cancer.
Rebekka has been involved in patent litigation at the district court level, as well as at the International Trade Commission. Her prosecution experience includes prosecuting worldwide patent portfolios, patent portfolio analysis and strategy development, and opinion work in the biotechnology and chemical arts.
In addition, Rebekka has co-authored several client opinion letters regarding the validity and extent of coverage of biotechnology patent estates. Her patent prosecution practice includes the prosecution of numerous biotechnology, chemical, pharmaceutical, and medical device patent applications now pending, including patent applications worldwide (PCT, EPO regional, and direct national). Rebekka has counseled licensors and licensees in the fields of biotechnology and pharmaceuticals and has drafted, reviewed, analyzed, and rendered opinions upon a number of patent licenses, and nondisclosure, technology transfer, and collaboration agreements. She has worked on several patent interferences related to biotechnology and pharmaceuticals. She also has analyzed patent, trademark, and copyright infringement positions and counseled clients regarding infringement by third parties, as well as potential infringement of a third party's intellectual property rights. Furthermore, she has handled domestic and international dockets of numerous biotechnology companies and research institutions and is well versed in foreign patent rules and procedures.
While studying for her master's degree at Harvard Medical School, Rebekka conducted research involving modified retroviral vectors encoding fas-related apoptosis proteins to evoke tumor-specific immune responses through vaccination as part of gene and immunotherapy for advanced malignant melanoma. She received numerous awards, including the National Science Foundation's Predoctoral Fellowship and a Harvard-Markey Biomedical Scientist Training Fellowship.
Rebekka has worked with Switzerland's Federal Institute of Intellectual Property, where she served as scientific adviser to the jurists drafting the revisions to the national patent laws in accordance with the European Union's Directive for Biotechnology Inventions.
Rebekka earned her B.S., magna cum laude, from the University of California San Diego, her M.M. Sc. from Harvard University and her J.D. from the University of California Los Angeles School of Law.